Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

• Egile Nagusiak: Jos Lommerse (Egilea), Diana Clarke (Egilea), Thomas Kerbusch (Egilea), Henri Merdjan (Egilea), Han Witjes (Egilea), Hedy Teppler (Egilea), Mark Mirochnick (Egilea), Edward P. Acosta (Egilea), Larissa Wenning (Egilea), Sharon Nachman (Egilea), Anne Chain (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2019-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite removal from the source of extrinsic raltegra...